Last reviewed · How we verify
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of A sintilimab plus chemotherapy followed by definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Details
| Lead sponsor | Fudan University |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 75 |
| Start date | Thu Oct 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Dec 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
- Sintilimab plus Chemotherapy
Countries
China